A citation-based method for searching scientific literature

Walter Masson, Augusto Lavalle-Cobo, Martín Lobo, Gerardo Masson, Graciela Molinero. Eur J Prev Cardiol 2021
Times Cited: 7







List of co-cited articles
21 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
57

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
57

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
57

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
57

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
42


SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
Carlos Escobar, Vivencio Barrios, Juan Cosín, José María Gámez Martínez, Ana Isabel Huelmos Rodrigo, Carolina Ortíz Cortés, Javier Torres Llergo, Carolina Requeijo, Ivan Solà, Mª José Martínez Zapata. Diabet Med 2021
5
40

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
Brendon L Neuen, Clare Arnott, Vlado Perkovic, Gemma Figtree, Dick de Zeeuw, Greg Fulcher, Min Jun, Meg J Jardine, Sophia Zoungas, Carol Pollock,[...]. Diabetes Obes Metab 2021
19
28

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Silvio E Inzucchi, David Fitchett, Dubravka Jurišić-Eržen, Vincent Woo, Stefan Hantel, Christina Janista, Stefan Kaspers, Jyothis T George, Bernard Zinman. Diabetes Obes Metab 2020
34
28



Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
634
28


10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
28


Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
Matthew J Crowley, Darren K McGuire, Anastasia-Stefania Alexopoulos, Thomas Jon Jensen, Søren Rasmussen, Hans A Saevereid, Subodh Verma, John B Buse. Diabetes Care 2020
15
28

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
28

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
829
28


Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
700
28


Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
14

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
Joshua D Wallach, Kun Wang, Audrey D Zhang, Deanna Cheng, Holly K Grossetta Nardini, Haiqun Lin, Michael B Bracken, Mayur Desai, Harlan M Krumholz, Joseph S Ross. BMJ 2020
29
14

Therapy of Type 2 Diabetes.
Rüdiger Landgraf, Jens Aberle, Andreas L Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller-Wieland, Michael A Nauck, Hans-Martin Reuter, Erhard Siegel. Exp Clin Endocrinol Diabetes 2019
5
20

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study.
Louise A Donnelly, John M Dennis, Ruth L Coleman, Naveed Sattar, Andrew T Hattersley, Rury R Holman, Ewan R Pearson. Diabetes Care 2020
6
16

Targets for blood glucose: What have the trials told us.
Paul Valensi, Gaëtan Prévost, Oliver Schnell, Eberhard Standl, Antonio Ceriello. Eur J Prev Cardiol 2019
8
14

Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update.
Lorraine Lipscombe, Sonia Butalia, Kaberi Dasgupta, Dean T Eurich, Lori MacCallum, Baiju R Shah, Scot Simpson, Peter A Senior. Can J Diabetes 2020
22
14

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetologia 2020
171
14

Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
Salim Yusuf, Philip Joseph, Sumathy Rangarajan, Shofiqul Islam, Andrew Mente, Perry Hystad, Michael Brauer, Vellappillil Raman Kutty, Rajeev Gupta, Andreas Wielgosz,[...]. Lancet 2020
253
14



Socioeconomic position and one-year mortality risk among patients with heart failure: A nationwide register-based cohort study.
Julie Andersen, Thomas Alexander Gerds, Gunnar Gislason, Morten Schou, Christian Torp-Pedersen, Mark A Hlatky, Sidsel Møller, Christian Madelaire, Katrine Strandberg-Larsen. Eur J Prev Cardiol 2020
7
14

Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure.
Giuseppe Boriani, Roberto De Ponti, Federico Guerra, Pietro Palmisano, Gabriele Zanotto, Antonio D'Onofrio, Renato Pietro Ricci. Eur J Prev Cardiol 2021
4
25

Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes.
Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini. Eur J Prev Cardiol 2021
6
16


Antithrombotic therapy in patients undergoing transcatheter aortic valve replacement: the complexity of the elderly.
Leonardo Bencivenga, Immacolata Sepe, Maria Emiliana Palaia, Klara Komici, Graziamaria Corbi, Brunella Puzone, Michele Arcopinto, Antonio Cittadini, Nicola Ferrara, Grazia Daniela Femminella,[...]. Eur J Prev Cardiol 2021
1
100

Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
Rafael Diaz, Qian H Li, Deepak L Bhatt, Vera A Bittner, Marie T Baccara-Dinet, Shaun G Goodman, J Wouter Jukema, Takeshi Kimura, Alexander Parkhomenko, Robert Pordy,[...]. Eur J Prev Cardiol 2020
9
14

Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
Francesco Prattichizzo, Lucia La Sala, Lars Rydén, Nikolaus Marx, Marc Ferrini, Paul Valensi, Antonio Ceriello. Eur J Prev Cardiol 2019
33
14

Long-term opiate use and risk of cardiovascular mortality: results from the Golestan Cohort Study.
Mahdi Nalini, Ramin Shakeri, Hossein Poustchi, Akram Pourshams, Arash Etemadi, Farhad Islami, Masoud Khoshnia, Abdolsamad Gharavi, Gholamreza Roshandel, Hooman Khademi,[...]. Eur J Prev Cardiol 2021
3
33

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Darren K McGuire, John H Alexander, Odd Erik Johansen, Vlado Perkovic, Julio Rosenstock, Mark E Cooper, Christoph Wanner, Steven E Kahn, Robert D Toto, Bernard Zinman,[...]. Circulation 2019
86
14

Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
Konstantinos C Koskinas, Baris Gencer, David Nanchen, Mattia Branca, David Carballo, Roland Klingenberg, Manuel R Blum, Sebastian Carballo, Olivier Muller, Christian M Matter,[...]. Eur J Prev Cardiol 2020
11
14

The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
Christopher Blaum, Moritz Seiffert, Alina Goßling, Friederike Kröger, Benjamin Bay, Thiess Lorenz, Julian Braetz, Annika Graef, Tanja Zeller, Renate Schnabel,[...]. Eur J Prev Cardiol 2021
3
33

Effect of persistent opium consumption after surgery on the long-term outcomes of surgical revascularisation.
Farzad Masoudkabir, Negin Yavari, Mina Pashang, Saeed Sadeghian, Arash Jalali, Hamidreza Poorhosseini, Seyed Hossein Ahmadi Tafti, Jamshid Bagheri, Kiomars Abbasi, Abbas Salehi Omran,[...]. Eur J Prev Cardiol 2020
5
20

The mediating role of effective treatments in the relationship between income level and survival in patients with heart failure: a sex- and cohabitation-stratified study.
Julie Andersen, Thomas A Gerds, Mark A Hlatky, Gunnar Gislason, Morten Schou, Christian Torp-Pedersen, Sidsel Møller, Christian Madelaire, Katrine Strandberg-Larsen. Eur J Prev Cardiol 2021
3
33


Association of four lipid components with mortality, myocardial infarction, and stroke in statin-naïve young adults: A nationwide cohort study.
Heesun Lee, Jun-Bean Park, In-Chang Hwang, Yeonyee E Yoon, Hyo Eun Park, Su-Yeon Choi, Yong-Jin Kim, Goo-Yeong Cho, Kyungdo Han, Hyung-Kwan Kim. Eur J Prev Cardiol 2020
15
14

Is the novel LDL-cholesterol goal <1.4 mmol/L achievable without a PCSK9 inhibitor in a chronic coronary population from clinical practice?
John Munkhaugen, Elise Sverre, Kari Peersen, Oscar Kristiansen, Erik Gjertsen, Lars Gullestad, Jan Erik Otterstad. Eur J Prev Cardiol 2020
3
33

Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL.
Harrison W Farber, David B Badesch, Raymond L Benza, C Gregory Elliott, Robert P Frantz, Michael D McGoon, Mona Selej, Carol Zhao, Adaani E Frost. J Heart Lung Transplant 2018
10
14

Dietary intakes of flavan-3-ols and cardiometabolic health: systematic review and meta-analysis of randomized trials and prospective cohort studies.
Gowri Raman, Esther E Avendano, Siyu Chen, Jiaqi Wang, Julia Matson, Bridget Gayer, Janet A Novotny, Aedín Cassidy. Am J Clin Nutr 2019
26
14

Stimulatory effects of the flavanol (-)-epicatechin on cardiac angiogenesis: additive effects with exercise.
Israel Ramirez-Sanchez, Leonardo Nogueira, Aldo Moreno, Ann Murphy, Pam Taub, Guy Perkins, Guillermo M Ceballos, Michael Hogan, Moh Malek, Francisco Villarreal. J Cardiovasc Pharmacol 2012
23
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.